MedTrace Logo

EU Secondary Data Post-Authorisation Safety Study of AZD1222

NCT05126992 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5321930

Last updated 2025-01-28

No results posted yet for this study

Summary

A study based on electronic heath records will evaluate the incidence and relative risk of safety concerns and adverse events of special interest (AESIs) following immunisation by AZD1222 in the real-world setting.

A cohort and a self-controlled case series desings will be used.

Conditions

  • COVID-19, Vaccine Adverse Events of Special Interest

Interventions

BIOLOGICAL

AZD1222

Covid-19 AstraZeneca Vaccine

Sponsors & Collaborators

  • RTI Health Solutions

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Principal Investigators

  • Cristina Rebordosa, MD, PhD · RTI

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-18
Primary Completion
2024-01-24
Completion
2024-01-24

Countries

  • Netherlands
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05126992 on ClinicalTrials.gov